{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 17 of 74', '7 Trial Design', '7.1 Statement of design', 'INTERIM is a multi-centre, open label, two-arm, randomised phase II feasibility trial', 'aimed at investigating the role of intermittent dosing of the combination BRAF and MEK', 'inhibitor regimen, dab+tram.', '7.2 Number of Centres', 'Approximately 20 UK sites will participate. INTERIM is centrally co-ordinated at the', 'Cambridge Clinical Trials Unit - Cancer Theme (CCTU-CT).', '7.3 Number of Patients', '150 patients will be randomised 1:1.', '7.4 Patients Trial duration', 'The time from consent to randomisation is up to 28 days. The duration of treatment is', \"until disease progression or beyond, at the investigator's discretion. A minimum of 9\", 'months follow-up from the date of randomisation is required for all surviving patients.', '7.5', 'Trial objectives', '7.5.1', 'Primary Objectives', 'To assess recruitment rate and treatment compliance of the intermittent dosing', 'schedule as a measure of acceptance of intermittent dosing to patients and', 'physicians', 'To evaluate the impact on overall QoL with intermittent dosing using European', 'Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30', 'To estimate the size of clinical efficacy of intermittent dosing compared to', 'continuous dosing, measured by PFS', '7.5.2', 'Secondary Objectives', 'To evaluate safety, objective response rate, time to treatment failure and overall', 'survival', 'To evaluate skin toxicity as assessed by clinicians and patients using patient', 'reported outcome measures (PROMS) (Skindex-16 and patient-reported', 'outcomes version of the Common Terminology Criteria for Adverse Events (PRO-', 'CTCAE))', \"To assess factors which influence patients' decision to enter/decline entering the\", 'trial', 'To evaluate patient experience of participation in this trial (using mixed', 'methods)', 'To determine the QoL and cost-effectiveness of intermittent dosing compared', 'with standard continuous dosing', '7.5.3', 'Exploratory Objectives', 'To explore emergence of resistance by means of ctDNA collected from patients', 'during the course of their treatment', 'To determine the role of ctDNA as a useful biomarker for therapeutic monitoring', 'In a subset of patients (up to 20), explore pharmacokinetics of standard versus', 'intermittent dosing schedules', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 18 of 74', '7.6 Trial Endpoints', '7.6.1', 'Primary Endpoints', 'Recruitment rate for endpoint analysis will be assessed once the trial has been', 'recruiting for 15 months, or when 15 sites have been open for 6 months,', 'whichever is sooner. It will be measured as the average number of patients', 'recruited per site per 2 months', 'Treatment compliance is defined as the percentage of patients completing the', 'allocated treatment at 6 months from the date of randomisation. Although the', 'primary aim is to assess the compliance of the intermittent dosing schedule,', 'compliance of the standard continuous dosing schedule will also be assessed and', 'compared with the experimental arm in an exploratory manner', 'Overall QoL is defined as the global health status score derived from the', 'standard EORTC QLQ-C30 questionnaire at 6 months from date of randomisation', 'PFS is calculated as the duration from date of randomisation to the date of first', 'progression or death from any cause, whichever occurs first. Progression is', 'assessed according to standard Response Evaluation Criteria In Solid Tumours', '(RECIST v1.1 - appendix 1)', '7.6.2', 'Secondary Endpoints', 'Safety is assessed using the standard cancer National Cancer institute (NCI)', 'CTCAE v4.03 criteria', 'Objective Response Rate is assessed according to RECIST v1.1 (Appendix 1)', 'Time to treatment failure is the time from starting drug treatment with', 'dabrafenib+trametinil on day 1 of cycle 1 until the date of day 1 of the last cycle +28', 'days;', 'Overall survival is calculated as the duration from the date of randomisation to', 'the date of death from any cause', 'Patient reported outcomes focussing on skin toxicity evaluation is assessed', 'using skin-specific patient reported outcome measures (PROM) - the Skindex-16', 'and NCI PRO-CTCAE', 'Patient experience is assessed by a) patient experience survey of patients in', 'each arm of the trial and b) semi-structured interviews in a subset of patients', 'who have volunteered', 'QoL & Health Economic Evaluation: the EORTO QLQ-C30 and EQ5D generic', 'measure of health status will be used for the cost-effectiveness analysis.', '7.6.3', 'Exploratory Endoints', 'Using blood and tumour tissue collected from recruited patients, we will explore:', 'the kinetics of BRAF mutation load in each arm of the trial', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}